| Literature DB >> 21640138 |
Hannah P Yang1, David K Walmer, Delson Merisier, Julia C Gage, Laura Bell, Sameera Rangwala, Niwashin Shrestha, Lori Kobayashi, Paul S Eder, Philip E Castle.
Abstract
The analytic performance of a low-cost, research-stage DNA test for the most carcinogenic human papillomavirus (HPV) genotypes (HPV16, HPV18, and HPV45) in aggregate was evaluated among carcinogenic HPV-positive women, which might be used to decide who needs immediate colposcopy in low-resource settings ("triage test"). We found that HPV16/18/45 test agreed well with two DNA tests, a GP5+/6+ genotyping assay (Kappa = 0.77) and a quantitative PCR assay (at a cutpoint of 5000 viral copies) (Kappa = 0.87). DNA sequencing on a subset of 16 HPV16/18/45 positive and 16 HPV16/18/45 negative verified the analytic specificity of the research test. It is concluded that the HPV16/18/45 assay is a promising triage test with a minimum detection of approximately 5000 viral copies, the clinically relevant threshold. Published by Elsevier B.V.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21640138 PMCID： PMC3155880 DOI： 10.1016/j.jviromet.2011.05.024
Source DB: PubMed Journal: J Virol Methods ISSN： 0166-0934 Impact factor: 2.014